Thursday, 15 October 2026European Markets

BW LPG Stock 12.28% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with BW LPG (BWLPG.OL) rising 12.28% to kr213.00 on Thursday while Oslo Børs Benchmark Index_GI rose 0.31% to kr1,428.10.

BW LPG's last close was kr189.70, 55.88% above its 52-week high of kr121.70.

About BW LPG

BW LPG Limited, an investment holding company, engages in ship owning and chartering activities worldwide. The company operates through Shipping and Product Services segments. The company involved in the transportation of liquefied petroleum gas to oil companies, and trading and utility companies. It also offers integrated liquified petroleum gas (LPG) delivery services and support; wholesale and trade of LPG; and management services. It owns and operates LPG vessels and a fleet of very large gas carriers. The company was formerly known as BW Gas LPG Holding Limited and changed its name to BW LPG Limited in September 2013. BW LPG Limited was founded in 1935 and is headquartered in Singapore.

Earnings Per Share

As for profitability, BW LPG has a trailing twelve months EPS of kr37.03.

PE Ratio

BW LPG has a trailing twelve months price to earnings ratio of 5.75. Meaning, the purchaser of the share is investing kr5.75 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.16%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 206.6%, now sitting on 2.17B for the twelve trailing months.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on May 26, 2023, the estimated forward annual dividend rate is 39.9 and the estimated forward annual dividend yield is 33.62%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BW LPG's stock is considered to be oversold (<=20).

More news about BW LPG (BWLPG.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com